Disease · EFO_1001801

intracranial subdural hematoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. intracranial subdural hematoma. Diseases, record EFO_1001801. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001801

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: intracranial subdural hematoma; Open Targets
Open Targets ID: EFO_1001801; Open Targets
Other names: Hematoma, Subdural, Intracranial, Subdural haematoma, Subdural haemorrhage, Subdural hemorrhage, intracranial hematoma, subdural, subdural hematoma, subdural intracranial hematoma; Open Targets
MeSH: D046648; MeSH
NCI Thesaurus: C116585; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 1 of its 16 drugs, from ClinicalTrials.gov; Open Targets

Drugs16

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TRANEXAMIC ACID	CHEMBL877	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 2/3	ClinicalTrials.gov	3	3	3	Drugs and targets
TOCILIZUMAB	CHEMBL1237022	Antibody	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
ATORVASTATIN	CHEMBL1487	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
FENTANYL	CHEMBL596	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
MAGNESIUM SULFATE	CHEMBL3989857	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PROPOFOL	CHEMBL526	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BROMOCRIPTINE	CHEMBL493	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
MEMANTINE	CHEMBL807	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
ACENOCOUMAROL	CHEMBL397420	Small molecule	Unknown	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 16

See all 16 drugs

Targets40

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PTGS1	Cyclooxygenase	3	Cyclooxygenase inhibitor	Unknown	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	3	Cyclooxygenase inhibitor	Unknown	https://conductscience.org/library/genes/5743	Drugs and targets
CHRNA1	Muscle-type nicotinic acetylcholine receptor	1	Muscle-type nicotinic acetylcholine receptor antagonist	Unknown	https://conductscience.org/library/genes/1134	Drugs and targets
CHRNB1	Muscle-type nicotinic acetylcholine receptor	1	Muscle-type nicotinic acetylcholine receptor antagonist	Unknown	https://conductscience.org/library/genes/1140	Drugs and targets
CHRND	Muscle-type nicotinic acetylcholine receptor	1	Muscle-type nicotinic acetylcholine receptor antagonist	Unknown	https://conductscience.org/library/genes/1144	Drugs and targets
CHRNE	Muscle-type nicotinic acetylcholine receptor	1	Muscle-type nicotinic acetylcholine receptor antagonist	Unknown	https://conductscience.org/library/genes/1145	Drugs and targets
CHRNG	Muscle-type nicotinic acetylcholine receptor	1	Muscle-type nicotinic acetylcholine receptor antagonist	Unknown	https://conductscience.org/library/genes/1146	Drugs and targets
DRD2	D2-like dopamine receptor	1	D2-like dopamine receptor agonist	Phase 1/2	https://conductscience.org/library/genes/1813	Drugs and targets
DRD3	D2-like dopamine receptor	1	D2-like dopamine receptor agonist	Phase 1/2	https://conductscience.org/library/genes/1814	Drugs and targets
DRD4	D2-like dopamine receptor	1	D2-like dopamine receptor agonist	Phase 1/2	https://conductscience.org/library/genes/1815	Drugs and targets

1 to 10 of 40

See all 40 targets

Trials15

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03496545	Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury	Phase 1/2	47	2021-06-24	Subarachnoid Hemorrhage, Subdural Hematoma, Traumatic Brain Injury, Ischemic Stroke, Fever, Intracerebral Hemorrhage	BROMOCRIPTINE	Its record names the disease	ClinicalTrials.gov
NCT02111785	Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma	Phase 2/3	10	2018-12-11	Chronic Subdural Hematoma	DEXAMETHASONE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02550717	Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)		398,158		Secondary Prevention, Stroke, Ischemic Heart Disease, Coronary Heart Disease	ASPIRIN, CLOPIDOGREL	Its record names the disease	ClinicalTrials.gov
NCT03353259	Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery	Phase 2/3	382		Chronic Subdural Hematoma	TOCILIZUMAB, TRANEXAMIC ACID	Open Targets' reading of its record	ClinicalTrials.gov
NCT02938468	Mgt of Chronic Subdural Hematoma Using Dexamethasone	Phase 2/3	326		Chronic Subdural Hematoma	DEXAMETHASONE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02024373	Effect and Safety Study of Atorvastatin to Treat Chronic Subdural Hematoma	Phase 2	200		Chronic Subdural Hematoma	ATORVASTATIN	Its record names the disease	ClinicalTrials.gov
NCT02568124	Tranexamic Acid in Chronic Subdural Hematomas	Phase 2/3	130		Chronic Subdural Hematoma	TRANEXAMIC ACID	Open Targets' reading of its record	ClinicalTrials.gov
NCT05713630	The Use of Tranexamic Acid in the Treatment of Symptomatic Subdural Hematoma	Phase 3	130		Subdural Hematoma	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT04898712	Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma -2	Phase 2	90		Chronic Subdural Hematoma	TRANEXAMIC ACID	Open Targets' reading of its record	ClinicalTrials.gov
NCT07143799	Scalp Block Versus General Anesthesia in Patients Undergoing Evacuation of Subdural Hematoma Via Burr Hole	Not applicable	80		Subdural Hematoma	CISATRACURIUM	Its record names the disease	ClinicalTrials.gov

1 to 10 of 15

See all 15 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Acetaminophen vs Bromocriptine and Acetaminophen: deaths from any cause	0 of 21	1 of 26	47	NCT03496545	Trial comparisons
Acetaminophen vs Bromocriptine and Acetaminophen: serious adverse events	0 of 21	1 of 26	47	NCT03496545	Trial comparisons

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
29093065	RESULT	1	PubMed
28371181	RESULT	1	PubMed
42423601	DERIVED	1	PubMed
35133631	DERIVED	1	PubMed
30073290	DERIVED	1	PubMed
27150916	DERIVED	1	PubMed
26581842	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_1001801

GET https://conductscience.org/api/diseases/v1/EFO_1001801/targets?page=2

API reference For AI assistants